Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07218354 · ClinicalTrials.gov registry record · Phase 3
Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of a GLP-1 Receptor Agonist Semaglutide in U.S. Veterans With Alcohol Use Disorder
A Phase 3 study, sponsored by VA Office of Research and Development.
- Not yet
- Registry status
- Phase 3
- Development phase
- 622
- Enrollment target
NCT07218354: Clinical Trial Phase 3 study, sponsored by VA Office of Research and Development.
NCT07218354 is a Phase 3 study that has not yet begun recruiting, run by VA Office of Research and Development. The registered enrollment target is 622 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07218354, a Phase 3 study, has not yet begun recruiting, sponsored by VA Office of Research and Development.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 622 participants
- Enrollment target
Study Summary
This clinical trial aims to test the effectiveness and safety of semaglutide, a GLP-1 receptor agonist, in treating moderate to severe alcohol use disorder (AUD) in Veterans. Participants who qualify will be randomly assigned to receive either semaglutide injections or placebo injections over a 28-week period, followed by a 4-week post-treatment safety assessment period. Participants receiving semaglutide will start with a low dose, gradually increasing to a maximum of 2.4 mg per week, depending on their tolerance. The primary measure of success will be a reduction in risky drinking, assessed through a reliable calendar-based interview method called the Timeline Follow-Back (TLFB), a well-validated calendar-based interview technique for recording daily alcohol consumption. The purpose of this research is to gather information on the effectiveness of semaglutide for treating AUD, potentially offering a new and more appealing treatment option.
Interventions
- DRUG Placebo
- DRUG Semaglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 622 participants |
| Start Date | 2026-07-01 |
| Est. Completion | 2029-05-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07218354
The ClinicalTrials.gov registry entry for NCT07218354 describes a study currently listed as not yet recruiting, categorized as Phase 3. The registered enrollment target is 622 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07218354 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07218354 about?
NCT07218354 is a clinical study titled "Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of a GLP-1 Receptor Agonist Semaglutide in U.S. Veterans With Alcohol Use Disorder". This clinical trial aims to test the effectiveness and safety of semaglutide, a GLP-1 receptor agonist, in treating moderate to severe alcohol use disorder (AUD) in Veterans. Participants who qualify will be randomly assigned to receive either semaglutide injections or placebo injections over a 28-w...
What is the current status of trial NCT07218354?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 622 participants. The study started on 2026-07-01. Estimated completion is 2029-05-26.
What interventions are being tested in trial NCT07218354?
The interventions under investigation include: Placebo (DRUG), Semaglutide (DRUG).
Who is sponsoring clinical trial NCT07218354?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.